Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;26(1):782-793.
doi: 10.1080/10717544.2019.1606865.

Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma

Affiliations

Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma

Mahfoozur Rahman et al. Drug Deliv. 2019 Dec.

Abstract

This work evaluates nano-lipid carrier of ganoderic acid (GA) and molecular docking on various cancer signaling pathways, an attempt to improve the hepatic condition associated with hepatic carcinoma (HCC) induced by diethyl-nitrosamine (DEN) in Wistar rats. Molecular docking mechanism of GA was performed through binding simulation analysis for various cancer signaling pathway, viz., Bcl-2, Pl3K, NF-κB, Akt/PKB, and Stat-3. Double emulsion solvent displacement method was implied for preparation of GA-loaded nano-lipid carrier. GA-NLCs were evaluated for drug loading capacity, entrapment efficiency, particle size, gastric stability, in vitro drug release, cytotoxicity, cellular uptake, and in vivo studies including macroscopical, hepatic injury markers, non-hepatic, biochemical, antioxidant parameters, and histopathological evaluation. HCC was induced by intraperitoneal injection of DEN (200 mg/kg). Both in vivo and molecular docking results were compatible in establishing the alteration in hepatic nodules, hepatic, non-hepatic, and antioxidant parameters, in a significant manner (p < .001) by GA and GA-NLC along with signal alteration of Bcl-2, Pl3K, NF-κB Akt/PKB, and Stat-3 pathway. Histopathological observation confirmed and supported the above result by GA and GA-NLC. On the basis of our results, we can advocate that, GA interferes with various cancer signaling proteins involved in pathogenesis of cancer and was able to cease the progression of disease. Additionally, GA-NLCs proved its chemoprotective effect against the DEN-induced HCC by modulation of hepatic and non-hepatic parameters through various mechanisms.

Keywords: Akt/PKB; Ganoderic acid; HepG2 cell; antioxidant; antioxidants enzymes; entrapment efficiency; hepatoprotective; nano-lipid carrier.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Uptake of (A) free coumarin-6 (C-6) and (B) C-6 loaded GA-nano-lipid carrier, upon incubation at 1 µg/mL for 2 h. In all the images, (a) images under the green fluorescence channel; (b) corresponding differential interface contrast images of HepG2 cells. (c) Superimposition of figure (a) and figure (b). (d, e) In all, the images show horizontal line series analysis of fluorescence along the white line.
Figure 2.
Figure 2.
Macroscopical observation of DEN-induced HCC group rats. (A) DEN control group showed the expansion of hepatic nodules (white in color) and decolorization of tissue, (B) DEN control group treated with GA (25 mg/kg) illustrated the expansion of pre-cancerous nodules (white in color) and decolorization of tissue color, which was less as compared to DEN group, (C) DEN control group treated with GA (50 mg/kg) demonstrated the less pre-cancerous nodules (white in color) and decolorization of tissue color, (D) DEN control group treated with GA (100 mg/kg) illustrated the expansion of pre-cancerous nodules and decolorization of tissue color, which was less as compared to other group, and (E) DEN control group treated with GA-NLC (25 mg/kg) illustrated the decolorization of tissue color, which was less as compared to other group rats. Note: Normal control and normal control rats treated with GA (100 mg/kg) did not show any sign of precancerous cells and decolorization of skin (data not shown).
Figure 3.
Figure 3.
The histopathological evaluation of DEN-induced HCC group rats. (A) DEN control group showed the expansion of hepatic nodules (white in color) and decolorization of tissue, (B) DEN control group treated with GA (25 mg/kg) illustrated the expansion of pre-cancerous nodules (white in color) and decolorization of tissue color, which was less as compared to DEN group, (C) DEN control group treated with GA (50 mg/kg) demonstrated the less pre-cancerous nodules (white in color) and decolorization of tissue color, (D) DEN control group treated with GA (100 mg/kg) illustrated the expansion of pre-cancerous nodules and decolorization of tissue color, which was less as compared to other group, and (E) DEN control group treated with GA-NLC (25 mg/kg) illustrated the decolorization of tissue color, which was less as compared to other group rats. Note: Normal control and normal control rats treated with GA (100 mg/kg) did not show any sign of alteration in the histopathology (data not shown).

References

    1. Ahmad N, Alam MA, Ahmad R, et al. (2018). Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. J Microencapsul 35:327–43. - PubMed
    1. Amarji B, Garg NK, Singh SB, et al. (2016). Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics. J Drug Target 24(2): 1–14. - PubMed
    1. Avachat AM, Parpani SS (2015). Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces 126:87–97. - PubMed
    1. Ayala A, Muñoz MF, Argüelles S (2014). Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014:360438. - PMC - PubMed
    1. Beg S, Sharma G, Thanki K, et al. (2015). Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm 493:466–82. - PubMed

MeSH terms